Table 3

Radiological characteristics of patients with COVID-19 with acute (myo)pericarditis (AMP) and comparison with non-COVID-19 patients with AMP (control group B)

Cases
(COVID-19 and AMP)
N=67
n (%)
Control group B
(non-COVID and AMP)
N=335
n (%)
P value
Analytical data
Raised troponin (above 99th of general population)22 (32.8)107 (31.9)0.89
NT-proBNP >900‚ÄČng/mL (n=16/53)11 (68.8)18 (31.3) 0.01
ECG
Diffuse ST elevation32 (47.8)202 (60.3)0.06
Diffuse PR depression14 (20.9)75 (22.4)0.79
Peaked T waves13 (19.4)46 (13.7)0.23
ST depression19 (28.4)92 (27.5)0.88
Atrial fibrillation14 (20.9)54 (16.1)0.34
Echocardiography (n=54/251)
Pericardial effusion26 (48.1)124 (49.4)0.87
Pericardial inflammation7 (13.0)20 (8.0)0.24
Right ventricular dysfunction11 (20.4)25 (10.0) 0.03
Left ventricular dysfunction17 (31.5)31 (13.9) 0.002
Ventricular hypokinesia/akinesia13 (24.1)36 (14.3)0.08
Treatment
Non-steroidal anti-inflammatory drugs48 (71.6)278 (83.0) 0.03
Colchicine23 (34.3)183 (54.6) 0.002
Corticosteroids22 (32.8)67 (20.0) 0.02
Need of inotropes14 (20.9)7 (2.1) <0.001
Final aetiological diagnosis
Idiopathic51 (76.1)262 (78.2)0.75
Bacterial5 (8.2)20 (6.3)0.59
Neoplasia4 (6.6)9 (2.8)0.24
Viral (confirmed by serological studies; not including SAR-CoV-2)3 (4.9)6 (1.8)0.18
Metabolic3 (4.9)1 (0.3) 0.02
Autoimmune2 (3.3)16 (5.0)0.75
Drug related1 (1.6)5 (1.6)1.0
Traumatism/iatrogenic0 (0)16 (5.0)0.09
Causes of death
All-cause death11 (16.4)8 (2.4) <0.001
Cardiovascular death3 (4.9)2 (0.6) 0.03
Non-cardiovascular death3 (4.9)4 (1.2)0.09
Unknown cause of death5 (8.2)2 (0.6) 0.002
  • Bold p values denote statistically significant differences (p<0.05).

  • NT-proBNP, N-terminal prohormone of brain natriuretic peptide.